MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Submission of Matters to a Vote of Security Holders
MediciNova, Inc. (the “Company”) held its 2019 annual meeting of stockholders on June 10, 2019 (the “Annual Meeting”). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the Securities and Exchange Commission on April 26, 2019 (the “Proxy Statement”).
At the close of business on April 11, 2019, the record date of the Annual Meeting, the Company had 43,061,161 shares of common stock issued and outstanding. The holders of a total of 30,681,971 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a quorum of the issued and outstanding shares on the record date of the Annual Meeting.
Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting
Final Voting Results
Final Voting Results
Final Voting Results
Final Voting Results
Final Voting Results
About MEDICINOVA, INC. (NASDAQ:MNOV)
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.
